Laurus Labs has announced a significant investment in its joint venture, KRKA Pharma Private Limited, amounting to up to €9.8 million. This strategic move, approved by the Board of Directors during their meeting on April 30, 2026, is aimed at supporting the joint venture’s capital expenditure plans for establishing a new manufacturing facility.
KRKA Pharma, a joint venture between Laurus Labs and KRKA d.d., Novo mesto, Slovenia, will also see an additional investment from KRKA d.d. amounting to approximately €10.2 million. The existing shareholding ratio will remain unchanged, with KRKA d.d. holding 51% and Laurus Labs maintaining a 49% stake.
The investment aligns with Laurus Labs’ long-term business objectives and strategic growth plans. The funds are expected to bolster KRKA Pharma’s capabilities in the pharmaceutical sector, where it currently operates. As of the financial year 2025-26, KRKA Pharma reported a turnover of ₹10.47 million.
The transaction qualifies as a related party transaction under SEBI regulations, given the common directors between Laurus Labs and KRKA Pharma. However, it is conducted at arm’s length, ensuring fairness and compliance with regulatory standards. The investment process is anticipated to conclude during the financial year 2026-27, with no governmental or regulatory approvals required.
KRKA Pharma, incorporated in April 2024, is yet to commence full-scale business operations but is currently engaged in research and development services. The joint venture is based in India and aims to expand its manufacturing capabilities through this investment.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).